Interest of fecal calprotectine dosage in inflammatory bowel diseases, state of the art and perspectives

Ann Biol Clin (Paris). 2016 Aug 1;74(4):385-94. doi: 10.1684/abc.2016.1172.

Abstract

Inflammatory bowel diseases are chronic diseases that result from an inflammation of the intestinal wall. They are suspected in any patient presenting with intestinal symptoms. Until recently, diagnosis was mainly based both on clinical and endoscopic arguments. The use of an easy, fast, reliable, non-invasive and inexpensive test must not only assist in the diagnosis but also contribute to their evolutionary and therapeutic monitoring. To date, fecal calprotectin is the most documented in this perspective. This marker allows to discriminate between functional and organic bowel processes with good sensitivity and good specificity. The determination of the fecal calprotectin level in stools contributes to the evaluation of the degree of disease activity and monitoring of therapeutic response.

Keywords: diagnosis; inflammation; inflammatory bowel diseases; intestines; stools; therapeutic follow-up.

Publication types

  • Review

MeSH terms

  • Biomarkers / analysis
  • Diagnosis, Differential
  • Diagnostic Tests, Routine / methods*
  • Diagnostic Tests, Routine / standards
  • Diagnostic Tests, Routine / trends
  • Feces / chemistry*
  • Humans
  • Inflammatory Bowel Diseases / diagnosis*
  • Inflammatory Bowel Diseases / metabolism
  • Leukocyte L1 Antigen Complex / analysis*
  • Leukocyte L1 Antigen Complex / metabolism
  • Monitoring, Physiologic
  • Predictive Value of Tests
  • Sensitivity and Specificity

Substances

  • Biomarkers
  • Leukocyte L1 Antigen Complex